您好,欢迎您

2026 ESMO|泌尿生殖系统肿瘤LBA标题出炉

09月22日
整理:肿瘤资讯
来源:2026 ESMO

2026年欧洲肿瘤内科学会年会(ESMO Congress 2026)将于当地时间10月23—27日在西班牙马德里召开,是全球肿瘤领域顶级学术会议之一。

目前ESMO官方已公布本届会议的口头报告标题及讲者信息。【肿瘤资讯】特梳理Presidential Symposium(主席研讨会)、Proffered Paper Session(优选口头报告)、Rapid Oral Session(快速口头报告)中的LBA研究。其中,泌尿生殖系统肿瘤领域LBA共5项

Presidential Symposium I

摘要号:LBA2

标题:Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: results from the Phase 3 VOLGA trial

中文标题:肌层浸润性膀胱癌围手术期度伐利尤单抗联合或不联合曲麦利尤单抗,并联合新辅助维恩妥尤单抗治疗:III期VOLGA试验结果

讲者:Thomas B. Powles (London, United Kingdom)

摘要号:LBA4 

标题:Darolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: interim analysis of an international, placebo-controlled, randomised phase 3 trial (DASL-HiCaP; ANZUP1801)

中文标题:达罗他胺联合雄激素剥夺治疗(ADT)及根治性或挽救性局部区域放疗用于局限性极高危前列腺癌:国际安慰剂对照随机III期DASL-HiCaP(ANZUP1801)试验中期分析

讲者:Tamim Niazi (Montreal, Canada, QC)

Proffered paper: Genitourinary tumours, prostate, penile and testils

摘要号:LBA53 

标题:Perioperative apalutamide (APA) plus androgen deprivation therapy (ADT) with radical prostatectomy plus pelvic lymph node dissection (RP + PLND) vs RP + PLND alone in patients (pts) with high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): PROTEUS Substudy

中文标题:高危局限性或局部晚期前列腺癌患者围手术期阿帕他胺(APA)联合雄激素剥夺治疗(ADT)及根治性前列腺切除术联合盆腔淋巴结清扫术(RP+PLND)对比单纯RP+PLND:PROTEUS子研究

讲者:Alberto Briganti (Milan, Italy)

Proffered paper 2: Genitourinary tumours, renal and urothelial

摘要号:LBA88 

标题:PErioperative PEmbrolizumab (P) plus metastasis-directed therapy (MDT) versus MDT alone in patients (pts) with oligometastatic renal cell carcinoma (omRCC): the randomized phase II PE-PE trial.

中文标题:寡转移肾细胞癌患者围手术期帕博利珠单抗(P)联合转移灶定向治疗(MDT)对比单纯MDT:随机II期PE-PE试验

讲者:Roberto Iacovelli (Rome, Italy)

Rapid oral: Genitourinary tumours, prostate, penile and testils

摘要号:LBA56 

标题:Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN-deficient metastatic hormone sensitive prostate cancer (mHSPC): updated overall survival (OS) from CAPItello-281

中文标题:PTEN缺失型转移性激素敏感性前列腺癌(mHSPC)患者:卡匹色替(capi)+阿比特龙(abi)对比安慰剂+阿比特龙——CAPItello-281研究总生存期(OS)更新数据

讲者:Karim Fizazi (Lille, France)


(官网持续更新中,如有疏漏,欢迎补充)

点击查看摘要原文链接


责任编辑:肿瘤资讯-TY
排版编辑:肿瘤资讯-TY

版权声明
本文专供医学专业人士参考。同时,欢迎个人转发分享,其他任何媒体、网站如需转载或引用本网版权所有内容,须获得授权,且在醒目位置处注明"转自:良医汇-肿瘤医生APP"。